A randomized, open-label, single-dose study to evaluate the safety and pharmacokinetics of two formulations containing 40 mg of fexuprazan in healthy Korean subjects
The novel 40-mg fexuprazan formulation (tablet A) was demonstrated to be bioequivalent to the initially developed formulation (tablet B), with comparable systemic exposure (AUC) and peak concentration (C<sub>max</sub>). Both formulations were well tolerated, with no clinically meaningful differences in adverse event profiles.
Authors
- Seol Ju Moon (ORCID: https://orcid.org/0000-0001-6484-2029)
- Min-Gul Kim
- Yong-Geun Kwak
- Joon Hur
- Jin A Lee
- Jihye Chae
- Yongam Choi
- Hyung Seok Park
Publication Details
- Journal
- International Journal of Clinical Pharmacology and Therapeutics
- Published
- 2026-02-22
- DOI
- https://doi.org/10.5414/cp204926
- Primary Topic
- Pharmacological Receptor Mechanisms and Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00